Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 6/11/2020)


Breast Cancer

Institution Study Title  
CUHK A Phase 3, multicenter randomized,open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), ananti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) forHER2-positive, unresectable and/or metastatic breast cancer subjects previouslytreated with trastuzumab and taxane Click for Details
CUHK A randomized, multicenter, open-label cross-over study to evaluate patientpreference and satisfaction of subcutaneous administration of the fixed-dosecombination of pertuzumab and trastuzumab in patients with her2-positive earlybreast cancer Click for Details
CUHK A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer Click for Details
HKU, QEH A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Click for Details
PYNEH, QEH A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases [Breast Cancer Radium-223] Click for Details
QMH A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Nab Paclitaxel Compared with Placebo with Nab Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer (WO29522) Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.